Mimo Biosciences

Mimo Biosciences operates as a specialized contract research organization (CRO) focused on advancing therapies against hematological cancers. The company was established in Pamplona, Spain, on February 1, 2024, as a spin-off from Cima Universidad de Navarra. Its foundation is built upon over a decade of research from the Hemato-Oncology laboratory at Cima, led by Dr. José Ángel Martínez-Climent, who is a founder and the Chief Scientific Officer of Mimo. The research, particularly the development of unique mouse models for multiple myeloma and lymphoma, was notably featured in Nature Medicine in 2023, which served as a catalyst for the company's creation. Cima licensed its know-how and granted Mimo exclusive worldwide rights to these models. Ricardo Pérez, who has an MBA, joined as CEO and is also a founder.

The firm's core business involves providing preclinical research services to pharmaceutical and biotechnology companies. It operates on a fee-for-service model, where it conducts studies using its proprietary animal models to test the efficacy and safety of new drugs. These models are a key differentiator, as the mice are genetically engineered to develop hematological diseases naturally, without the injection of tumor cells, which is expected to yield more robust and reliable data compared to conventional methods. Mimo's services encompass the entire preclinical process, from model implementation and disease tracking using in vivo imaging to detailed data analysis with biostatistics, bioinformatics, and an AI platform. The company serves a global clientele, with a significant portion of its clients based in the United States.

The company's offerings are highly customized, creating tailored preclinical tools for specific client projects, ranging from biomarker validation to large-scale efficacy trials. This includes developing genetically engineered mouse models (GEMMs), patient-derived xenografts (PDX), and humanized xenograft models. Mimo is also expanding its portfolio to include models for various B-cell lymphoma subtypes. After securing a capital increase in late 2024, the company is focused on consolidating its position in the multiple myeloma market and expanding into other myelomas and lymphomas. In May 2025, Mimo planned to move into new 400-square-meter facilities on the University of Navarra's campus, further enhancing its research capabilities.

Keywords: preclinical CRO, hematological oncology, immuno-oncology, multiple myeloma research, lymphoma models, preclinical studies, contract research organization, genetically engineered mouse models, GEMMs, patient-derived xenografts, PDX, in vivo studies, cancer therapy, drug development, Cima Universidad de Navarra spin-off, José Ángel Martínez-Climent, Ricardo Pérez, biopharmaceutical services, preclinical animal models, cancer research models